Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Psirelax is an herbal topical medication developed for the treatment of chronic plaque psoriasis. It is formulated as a cream containing a complex blend of natural ingredients, including quince seed jelly, wheat germ oil, sweet almond oil, jojoba oil, grape seed oil, sunflower oil, and beeswax. The product acts as an emollient and moisturizer with potential anti-inflammatory and immune-modulating properties, aimed at reducing psoriatic plaque severity, erythema, and desquamation. Clinical studies conducted in Israel have demonstrated significant reductions in Psoriasis Area and Severity Index (PASI) scores, with the product being well-tolerated and free of corticosteroids. It is licensed by the Israeli Ministry of Health and has been recommended by health services such as Maccabi and Clalit.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Psirelax.